2015 ACR/ARHP Annual Meeting

November 6-11, 2015. San Francisco, CA.

View by Number View by Title View Sessions

View by Date

Abstract Number: 1300

Comparison Between Semiquantitative and Quantitative Methods for the Assessment of Knee Synovitis Using Non-Enhanced and Gadolinium-Enhanced MRI
Abstract Number: 1301

Pain Central Sensitization Assessed By Functional Magnetic Resonance Imaging in Patients with Knee Osteoarthritis
Abstract Number: 1302

Inflammation Signs on Magnetic Resonance Imaging in Chronic or Recurrent Gonarthritis Treated with Intra-Articular Infliximab or Corticosteroids
Abstract Number: 1303

Is MRI More Sensitive Than Conventional Radiographs to Detect Hand Osteoarthritis Progression over 5 Years Follow-up?
Abstract Number: 1304

Studying MR-Detected Inflammation in Symptom-Free Persons from the General Population to Generate Ramris-Based Reference Values
Abstract Number: 1305

Prevalence of MR-Detected Ramris-Defined Erosions in the General Population
Abstract Number: 1306

MRI Erosions in Undifferentiated Arthritis. Different Associations with the Collagen IIA N-Terminal Propeptide (PIIANP) and Galectin-3 in Pre-RA and Other Arthritides
Abstract Number: 1307

Does Computerized Segmentation of Early Erosions on Magnetic Resonance Imaging Predict Functional Ability in Rheumatoid Arthritis?
Abstract Number: 1308

MRI Measures of Disease Activity and Joint Damage Are Associated with Patient-Reported Outcomes in Rheumatoid Arthritis
Abstract Number: 1309

Defining an Acceptable Level of MRI Inflammation in Rheumatoid Arthritis
Abstract Number: 1310

Efficacy of Abatacept in Patients with Rheumatoid Arthritis Assessed By MRI Scans of Bilateral Hands
Abstract Number: 1311

Effect of a Non Biologic Treat-to-Target Strategy on MRI-Determined Inflammatory and Destructive Changes in Early Rheumatoid Arthritis – Results from a 2-Year Investigator-Initiated Double-Blind Randomized Controlled Clinical Trial
Abstract Number: 1312

Radiocarpal Cartilage Matrix Changes 3-Months after Anti-TNF Treatment for Rheumatoid Arthritis – Feasibility Study Using MR T1ρ� Imaging
Abstract Number: 1313

Tumour Necrosis Factor Inhibitor Treatment Normalises Hand Bone Loss in a Minority of Rheumatoid Arthritis Patients Treated in Clinical Practice. Results from the Copenhagen Osteoarthritis Study and the Danbio Registry
Abstract Number: 1314

Quantitative MRI Measurement of Tenosynovitis Demonstrates Differing Responses of Synovitis and Tenosynovitis after RA Treatment

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].